Ependymal cells are multi-ciliated cells that form the brain's ventricular epithelium and a niche for neural stem cells (NSCs) in the ventricular-subventricular zone (V-SVZ). In addition, ependymal cells are suggested to be latent NSCs with a capacity to acquire neurogenic function. This remains highly controversial due to a lack of prospective in vivo labeling techniques that can effectively distinguish ependymal cells from neighboring V-SVZ NSCs. We describe a transgenic system that allows for targeted labeling of ependymal cells within the V-SVZ. Single-cell RNA-seq revealed that ependymal cells are enriched for cilia-related genes and share several stem-cellassociated genes with neural stem or progenitors. Under in vivo and in vitro neural-stem-or progenitor-stimulating environments, ependymal cells failed to demonstrate any suggestion of latent neuralstem-cell function. These findings suggest remarkable stability of ependymal cell function and provide fundamental insights into the molecular signature of the V-SVZ niche.
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In Brief
Targeted labeling of ependymal cells in a transgenic mouse model provides insights into the molecular signature of the ventricular-subventricular zone niche but is not consistent with ependymal cell neurogenic capacity at that site.
INTRODUCTION
The ventricular-subventricular zone (V-SVZ) of the adult mammalian brain, lying adjacent to the lateral ventricles, contains a cluster of stem cells that generates neurons, astrocytes, and oligodendrocytes throughout development, which could be directed to endogenously repair brain structures. The cytoarchitecture within the V-SVZ consists of a monolayer of ependymal cells, GFAP +ve neural stem (type B) cells, transit amplifying progenitors, and neuroblasts (Lim and Alvarez-Buylla, 2016) . Two characterized subpopulations of ependymal cells exist: most prominently, multi-ciliated (E1) ependymal cells, but also a rare subset of bi-ciliated (E2) ependymal cells (Mirzadeh et al., 2008 (Mirzadeh et al., , 2017 . Ependymal cells are a ciliated epithelial interface between the brain parenchyma and fluid-filled ventricles that form the wall of the ventricular system and a niche for type B neural stem cells (NSCs) in the V-SVZ (Lim and AlvarezBuylla, 2016) .
Although it is well established that ''sub-ependymal'' GFAP +ve type B cells are putative NSCs, the stem-cell-like plasticity of ependymal cells has been contentiously debated (Carlé n et al., 2009; Luo et al., 2015) . There is consensus that adult ependymal cells are post-mitotic under homeostasis (Spassky et al., 2005) . However, ependymal cells may represent a population of ''dormant'' NSCs, which are maintained in a state of quiescence via Notch signalling but convert to a neurogenic state in response to certain stimuli such as local striatal injury or bFGF and VEGF exposure (Carlé n et al., 2009; Luo et al., 2015) . Indeed, a number of mature tissue-resident cells have been shown to acquire alternative fates following stimuli such as injury (Kopp et al., 2016; Magnusson et al., 2014; Merrell and Stanger, 2016) . If ependymal cells could be coaxed to acquire alternative fates, this may hold significant clinical potential given that ependymal cells greatly outnumber type B NSCs (Mirzadeh et al., 2008) and populate the entirety of the brain's ventricular system, making them easily accessible for therapeutic activation. However, any bona fide neurogenic ability of ependymal cells has remained contentious, since distinguishing ependymal cells and type B NSCs (or their progenitor descendants) in vivo is difficult. In addition to both cells being derived from radial glia cells, in the adult V-SVZ, these cells share numerous phenotypic markers such as mCD24, Sox2, Nestin, and CD133 (Beckervordersandforth et al., 2010; Doetsch et al., 2002; Merkle et al., 2004; Spassky et al., 2005; Tavazoie et al., 2008) . FACS purified CD133 +ve GFAP Àve cells from the V-SVZ have been defined as ependymal cells; however, this is not sufficient, as other GFAP Àve cells such as oligodendrocytes and circulating precursors may also be captured (Beckervordersandforth et al., 2010; Llorens-Bobadilla et al., 2015; Luo et al., 2015; Peichev et al., 2000; Wu et al., 2014) . The FoxJ1 promoter was originally used for lineage tracing of V-SVZ ependymal cells, but it was found to be also expressed in postnatal V-SVZ NSCs (Beckervordersandforth et al., 2010; Carlé n et al., 2009; Devaraju et al., 2013; Jacquet et al., 2009 Jacquet et al., , 2011 ; Paez-Gonzalez et al., 2011).
Ultimately, although several studies suggest that ependymal cells contain stem cell properties, these conclusions have all been confounded by the possibility of contaminant labeling of non-ependymal NSCs in the V-SVZ. A key gap that remains to be filled is a comprehensive understanding of ependymal cell function and plasticity in the healthy and injured brain.
To directly assess the controversy surrounding the neurogenic capacity of ependymal cells, we developed a novel transgenic mouse model for the widespread targeting of ependymal cells at the exclusion of neural lineages within the postnatal V-SVZ. Contradictory to recent suggestions (Luo et al., 2015) , we find ependymal cells at large are Flt1, FN1-negative and have a remarkable lack of stemness or neurogenic capacity in vivo. We also find that ependymal cells have a distinct transcriptional signature, enriched for cilia-related genes, despite sharing a number of stem-cellassociated genes with neural stem and progenitor cells. These findings suggest the remarkable stability of ependymal cell function and provide fundamental insights into the molecular signature of the V-SVZ niche.
RESULTS

Genetic Labelling of Ependymal Cells in the Brain Using aSMACreER T2 Transgenic Mice
Actin and other cytoskeletal proteins are reported to be important for the maturation and planar cell polarity development of V-SVZ ependymal cells, so we first examined whether they could be used to distinguish ependymal cells from V-SVZ NSCs (Ohata and Alvarez-Buylla, 2016 tdTomato ; referred to as aSMA::R26) has been previously characterized to study hair follicles and smooth muscle cells (Moiseenko et al., 2017; Rahmani et al., 2014) . We found that postnatal (P40/41) tamoxifen-induced recombination (Figure 1A) in the aSMA::R26 system resulted in labeling of cells directly lining the walls of the lateral ventricles of the brain ( Figure 1B ). As suggestive of mature ependymal cells, these cells were multi-ciliated and expressed acetylated-Tubulin, CD133 (Prominin1), and FoxJ1 ( Figures  1C-1E ). All recombined cells along the ventricular wall were CD133 +ve , and 71.4% ± 4.9% of CD133 +ve cells lining the wall were recombined (n = 3 mice). ''En-face'' analysis of b-cateninimmunostained whole mounts demonstrated that recombined cells appeared in pin-wheel organizations, as expected of ependymal cells (Mirzadeh et al., 2008) . There was an absence of reporter labeling in the center of pinwheels where type B NSCs make ventricular contact ( Figure 1F ). In addition, we also observed recombined ependymal cells extending a single, long process along the ventricular wall ( Figure 1G ). To further define the identity of aSMA::R26 recombined cells lining the wall, we performed colocalization studies using a battery of V-SVZ cell-identity markers. As expected of ependymal cells, recombined cells also co-labeled with Sox2 and Nestin ( Figures 1H and 1I ) (Tavazoie et al., 2008) along with several sub-ependymal cells. Importantly, cells marked by aSMA::R26 in the V-SVZ did not exhibit astrocytic morphology, showing only rare co-expression of GFAP (GFAP +ve : 5/159 cells, n = 6 mice, Figure 1J ) yet were closely associated with GFAP +ve subependymal cells and were non-proliferative, as evidenced by an absence of Ki67 staining (Ki67 +ve : 0/47 cells, n = 3 mice; Figure 1K ). As expected of the aSMA promoter, other recombined cells identified throughout the brain were from mural cells, including smooth muscle cells associated with CD31
+ve blood vessels and a previously described rare population of integrin a9 +ve densely fibrous putative pericyte-precursors (Figures S1A and S1B; Sharma et al., 2012) . Critically, after 2-5 months of fate mapping, we found no evidence of recombined cell contribution to olfactory bulb neurogenesis (0 cells, n = 5 mice, Figure 1N ). We next wanted to understand the time course of genetic targeting of ependymal cells in aSMA::R26 mice. Ependymal cell or type B NSC fate in radial glia is determined largely by embryonic day (E) 15.5 (Fuentealba et al., 2015; Spassky et al., 2005) . Intriguingly, tamoxifen administration at E17 did not label any cells along the ventricular lining despite successful recombination in vascular cells ( Figure 1M) ; however, induction at P3+4 marked a subset of cells lining the ventricles by P8 ( Figure 1N ). We found examples of both ciliated and un-ciliated cells, with some extending a single, deprecated radial-glia-like process away from the V-SVZ. Fate mapping of these cells into adulthood (up to 5 months later) demonstrated labeling of multi-ciliated ependymal cells in the V-SVZ ( Figure 1N' ) and no labeling of astrocytic or neural progenitor cells. Moreover, induction at P3+4 resulted in a pattern of labeling closely reflecting previously described rostro-caudal and dorso-ventral pattern of ependymal cell maturation ( Figure 1N '', Spassky et al., 2005) . This suggests that aSMA::R26 is activated in immature, yet committed, ependymal cells on their way to fully mature into ependymal cells.
Adult Ependymal Cells Do Not Survive or Proliferate
In Vitro under Pro-growth Conditions Like NSCs, it has been suggested that V-SVZ ependymal cells can form clonal colonies under neurosphere growth conditions (Coskun et al., 2008) . To test the in vitro colony forming capabilities of ependymal cells, we FACS collected aSMA::eYFP +ve cells and aSMA::eYFP Àve cells from the microdissected adult V-SVZ and plated them in parallel under various NSC growth conditions (Figure 2A ). Within 1 week, we observed robust colony formation in aSMA::eYFP Àve cell cultures, but aSMA::eYFP +ve cell cultures showed no proliferative capacity for up to 2 weeks of culture ( Figures 2B and 2C ). These cells failed to proliferate when grown in the presence of FGF2+EGF or VEGF+FGF2+EGF, as well as in co-culture with E13 NSCs or with conditioned media collected from E13 neurosphere cultures ( Figure 2C ). To exclude the likely contamination of aSMA::eYFP +ve non-ependymal cells (e.g. mural cells), we developed a double-transgenic reporter system using Sox2-eGFP transgenic reporter mice, which reports Sox2 expression in the V-SVZ and throughout the adult brain and spinal cord (Ferri et al., 2004; Suh et al., 2007) , as well as in 83.4% ± 2.2% (n = 3 mice) of aSMA::R26 ependymal cells in the V-SVZ. Àve , whereas aSMA::tdTomato +ve cells from the V-SVZ were both Sox2
Àve and Sox2 +ve (Figure 2D ). aSMA::tdTomato +ve Sox2-GFP +ve cells from the V-SVZ often had multiple cilia ( Figure 2E ) and exhibited motile behavior that is characteristic of ependymal cells in culture (Laywell et al., 2000) , neither of which were observed in cells from cortical Figure 2E ). As suggested previously (Doetsch et al., 1999) experiments), much less proliferate, in sphere-forming conditions ( Figure 2E ).
Single-Cell Transcriptional Profiling of Ependymal Cells and Neural Stem or Progenitor Cells
To better characterize the transcriptional profile of ependymal cells relative to neural stem or progenitor cells, we performed single-cell transcriptomic analysis on micro-dissected V-SVZs (Figure 3A Figures S2A-S2F . Each sample was sequenced to an average depth of 49 million reads, and all samples were subsequently aggregated to a total of 1,700 barcoded cells. Low-quality cells with <400 genes detected were excluded, as were genes detected in <3 cells. We performed graph-based clustering using 2,985 highly variable genes, projected onto a tSNE plot, to explore cell clustering. We found that cells from the aSMA::tdTomato +ve Sox2-GFP +ve sample largely clustered distinctly apart from the aSMA::tdTomato Àve Sox2-GFP +ve sample ( Figures 3B and S2A ). This was not due to separate processing of each sample, as two individually processed aSMA::tdTomato Àve Sox2-GFP +ve cell samples showed remarkably concordant clustering ( Figure S2A ). Nine unique cell clusters emerged from our single-cell RNA-seq experiment ( Figure 3B ). Using previously established expression patterns of selected genes and the top five markers found for each cell population ( Figures 3C and 3D Figure 3D ). A small number of aSMA::tdTomato Àve Sox2-GFP +ve cells (23%) also appeared in this cluster and were presumed to be ependymal cells that escaped recombination ( Figure 3B ). Most aSMA::tdTomato Àve Sox2-GFP +ve cells were found in a chain of clusters that traversed the tSNE projection and were enriched in several neural lineage genes ( Figure 3B ). At one end was a cluster of cells enriched in a number of identified markers of quiescent NSCs (qNSCs) such as Clu, Gja1, Sox9, S100b, and Ntsr2 ( Figure 3D ) (Dulken et al., 2017; Llorens-Bobadilla et al., 2015) . Interestingly, expression of Clu, Gja1, Sox9, and S100b, but not Ntsr2, was also found in the ependymal cell cluster ( Figure 3D ). In total, we observed 2,375 shared genes between ependymal cells and qNSCs, whereas only 193 and 128 genes, respectively, were unique to ependymal cells or qNSCs (p > 0.01 or log2 fold change < 1, Figures S3A and S3B). The largest cluster of aSMA::tdTomato Àve Sox2-GFP +ve cells was strongly enriched for the neuroblast marker, Dcx. Between qNSC and neuroblast clusters, there were two clusters that expressed markers such as Thbs4 and Cdk1 and were classified as activated NSCs, with the latter likely representing an aNSC-late population ( Figure 3D ; Benner et al., 2013; Dulken et al., 2017) . We also identified several other distinct clusters in our dataset. The largest of these clusters contained cells from all samples and was overrepresented by oligodendroglia lineage genes such as Sox10, Plp1, and Mbp ( Figures 3C and 3D ). We also found small clusters containing only aSMA::tdTomato +ve Sox2-GFP +ve cells positioned distinctly away from the primary ependymal cell cluster. One of these clusters notably expressed Flt1 (''undefined cluster 1''), a second expressed Cx3cr1 (a microglia marker), and a final cluster was enriched for Vtn (''undefined cluster 2'').
Flt1-Expressing Cell Cluster Does Not Represent Ependymal Cells at Large
A previous study published in Cell used CD133 to reportedly isolate V-SVZ ependymal cells and ascribe them a transcriptional signature that included Flt1 (VEGF-receptor) and a number of other angiogenesis and hematopoietic-lineage-related genes (Luo et al., 2015) . We further examined the Flt1-expressing cell cluster that was captured in our dataset, and in contrast to our primary ependymal cell cluster, we found a complete absence of cilia-related genes previously shown to be associated with ependymal cells or found in association with cilia under GO term annotations ( Figure 4A ; Zeisel et al., 2015) . Interestingly however, this Flt1-expressing cell cluster showed an expression pattern (e.g., Slco1a4, Spock2, Cldn5, Kdr, and Fn1) that was remarkably consistent with the signature described for Flt1-expressing ependymal cells by Luo et al. (2015) . We were unable to detect immunoreactivity of VEGFR1 (Flt1) (using an Abcam antibody consistent with Luo et al., 2015) or FN1 in aSMA::R26-labeled ependymal cells lining the walls of the V-SVZ despite clearly positive labeling of blood vessels, choroid plexus, and/or the meningeal lining in the same brain ( Figures 4C and 4D ).
VEGF Infusion Does Not Result in Ependymal Cell
Activation Although it appears that aSMA::R26 ependymal cells are Flt1 negative (Figure 4 ) and are not neurogenic or proliferative in the uninjured brain or in vitro (Figures 1 and 2) , Luo et al. (2015) had suggested that Flt1-positive, CD133-labeled ependymal cells may be stimulated as neural stem cells in response to VEGF+bFGF exposure in vivo. Given the fact that our genetic labeling approach captures definitive ependymal cells, as well as a rare subset of cells expressing Flt1, we tested if any V-SVZ aSMA::R26-labeled cells in our system could be activated by direct infusion of exogenous VEGF+bFGF into the lateral ventricle. To do this, we injected either VEGF+bFGF (n = 3) or PBS (as control, n = 3) into the ventricle of adult aSMA::R26 mice, administered EdU for 1 week, and then assessed the cellular response at 1 week post-stimulation ( Figure 5A ). We observed a robust increase in the density of EdU-labeled proliferative cells (p < 0.001) compared to PBS control animals ( Figure 5B ). VEGF treatment resulted in significantly higher numbers of GFAP +ve EdU +ve -labeled cells, but not Dcx +ve EdU +ve neuroblasts, in the V-SVZ (p < 0.01, PBS versus VEGF+bFGF, n = 3 mice/group, Figures 5B-5D ). Notably, no recombined cells lining the ventricle or in the adjacent striatal parenchyma ever incorporated EdU or labeled for GFAP or Dcx in either group. As in the PBS control group, all recombined cells in the adjacent striatal parenchyma were GFAP Àve and
Dcx
Àve and appeared to be mural or smooth muscle cells closely associated with CD31 +ve blood vessels; similarly, their cell density remained unchanged following ventricular VEGF+bFGF administration ( Figure 5E ).
Striatal Injury Does Not Induce Proliferation, Delamination, or Differentiation of Neonatal or Adult V-SVZ Ependymal Cells
It remains a possibility that brain injury may be necessary to ''awaken'' neurogenic or proliferative programs within V-SVZ ependymal cells (Carlé n et al., 2009) . To test this, we induced striatal intracerebral hemorrhagic (ICH) stroke in aSMA::R26 mice using an unilateral injection of collagenase (or PBS as controls) to produce a spatially prescribed, reproducible injury (directly adjacent to the V-SVZ, Figure 6A ) consisting of both necrotic and ischemic tissue injury (Lok et al., 2011) . At 1 and 4 weeks post-injury, we did not observe any change in the density of aSMA::R26 +ve ependymal cells lining the V-SVZ following stroke (p = 0.17; n = 3-6 mice/group, Figure 6B ). As previously found in ischemic striatal stroke injury (Young et al., 2013) , we found ependymal cells in the ipsilateral V-SVZ responded acutely by expressing GFAP at 1 week post-stroke, which was diminished by 4 weeks (p < 0.05 versus 1 week PBS, n = 3 mice/group, Figure 6C ). That being said, none of these GFAP +ve ependymal cells adopted a star-shaped morphology ( Figure 6C ). To track cell division, we injected EdU during the first week or second and third weeks following stroke. Interestingly, we did not observe any evidence of EdU incorporation in aSMA::R26 +ve ependymal cells lining the lateral wall at any time point ( Figure 6D ). Instead, there was a marked increase in the density of EdU +ve GFAP +ve cells present within the V-SVZ region at 1 week post-stroke (p < 0.01 versus 1 week PBS, n = 3 mice/group, Figure 6D ), confirming that ICH injury was sufficient to activate resident cells within the V-SVZ. None of the recombined cells outside of the ependyma were immunoreactive for GFAP or Dcx but appeared to be mural or smooth muscle cells due to their close apposition to CD31 +ve blood vessels and did not change in cell density following injury ( Figure 6E ). Surrounding the lesion, there was marked GFAP +ve astrogliosis, as well as a progressive increase in numbers of Dcx +ve neuroblasts over time (p < 0.01; 4 weeks stroke versus PBS, n = 3-6 mice/group, Figures 6F, 6G, and 6G'). Importantly, neither population co-expressed the aSMA::R26 reporter ( Figures 6F, 6G , and 6G''). Thus, despite a significant stroke-induced neurogenic response, we found no evidence of neurogenesis derived from ependymal cells for up to 4 weeks following injury. We then surmised that immature ependymal cells might harbor greater plasticity. We induced hemorrhagic stroke in the striatum of neonatal (P10) aSMA::R26 mice that were administered tamoxifen at P4+5 (Figure S4A ). The response was identical to that observed in adult brains such that aS-MA::R26 +ve cells remained fixed along the V-SVZ wall (Figure S4B ). These aSMA::R26 +ve cells were not immunoreactive for the proliferative marker, Ki67 (0/111 recombined cells, n = 4 mice), despite the presence of widespread Ki67 immunoreactivity in adjacent cells (Figures S4B' and S4B'') and Dcx +ve neuroblasts in the injured striatum ( Figures S4C and S4C' ). NSCs, and neuroblasts in our RNA-seq dataset (Figure 7) . PAGODA identifies overdispersion of coordinated expression patterns of gene sets defined by gene ontology (GO), as well as discovering de novo gene sets (Fan et al., 2016) . These gene sets are further summarized to ''aspects,'' and examination of these associative aspects revealed that ependymal cells shared one aspect with qNSCs (enriched in neural development-related GO terms) and a second aspect with aNSCs enriched in microtubule-associated processes but were uniquely enriched in an aspect largely dominated by cilia-related processes ( Figure 7A ). Multiple aspects containing cell-cycle-and nuclear divisionrelated GO terms, as well fate-specifying genes such as Dlx1, were overdispersed in aNSCs, aNSCs late, and neuroblasts. Interestingly, we also found an aspect that was exclusive to qNSCs and was made up of only a small number of gene sets, which were largely uncharacterized. For example, the top three gene sets driving this aspect were all de novo gene sets. Interestingly, de novo gene set #1 (cZ = 16.32) contained genes with consistent expression across all qNSCs, whereas the remaining two gene sets (gene set #3, cZ = 13.63; and gene set #2, cZ = 11.60) showed substantial heterogeneity in expression of their respective genes within qNSCs ( Figure 7B ). We performed ingenuity pathway analysis on the top de novo gene set (gene set #1) enriched in the qNSCs aspect and found enrichment of the GO biological processes: glutamine-family amino-acid metabolism (fold enrichment: 40.17, p = 2.74eÀ02) and nervous system development (fold enrichment: 3.85, p = 4.98eÀ02). This analysis suggests that, despite considerable sharing of gene expression between ependymal cells and NSCs, there are several unique sets of genes that are likely important for divergent functions.
DISCUSSION
Until now, studying adult ependymal cells has been complicated by a lack of efficient and accurate tools that allow for prospective identification, isolation, and in vivo lineage tracing. The tamoxifen-inducible aSMACreER T2 transgenic system described here specifically targets ependymal-fated cells in the V-SVZ during the process of ependymal cell maturation and persists throughout adulthood. Although both ependymal cells and type B cells are derived from the same radial glia lineage, our data provide compelling evidence that only the latter retains their ancestral stem cell capacity in the postnatal brain. The promoter for FoxJ1, a transcription factor for motile cilia generation, has been previously used to drive in vivo genetic targeting of V-SVZ ependymal cells; however, it appears that A) Induction of striatal intracerebral hemorrhagic stroke induced by stereotaxic infusion of collagenase into adult aSMA::R26 mice. A large striatal haematoma forms adjacent to the subventricular zone present at 1 day post-stroke. EdU was administered either during the first or second and third weeks post-injury. (B) Representative images of aSMA::R26 recombined cells (green) lining the walls of the V-SVZ adjacent to the injured striatum. There were no differences in the density of recombined ependymal cells in the V-SVZ between ipsilateral versus contralateral to the lesion at either 1 week or 4 weeks post-stroke (p = 0.17, one-way ANOVA followed by a Tukey's post hoc test, n = 3-6 mice/group). (C) Upregulation of GFAP (red, arrowhead) in recombined ependymal cells (green) at 1 week post-stroke (Stroke) compared to sham (PBS) (C) . Quantification of GFAP co-expression in recombined ependymal cells at 1 week post-stroke compared to PBS (* p < 0.05, one-way ANOVA followed by Tukey's post hoc test, n = 3-6 mice/group). (D) Representative images demonstrating that recombined ependymal cells (green) did not incorporate EdU at 1 week following either sham injury (PBS) or hemorrhagic stroke (right). In contrast, frequent EdU +ve cells (red) were found directly beneath the ependymal cell layer (D). Quantification of ependymal (aSMA::R26 +ve EdU +ve ) and subependymal cell proliferation (aSMA::R26 Àve EdU +ve ± GFAP +ve ) in the V-SVZ at 1 and 4 weeks following stroke (* p < 0.01, oneway ANOVA followed by a Tukey's post hoc test, n = 3-6 mice/group). (E) CD31 expression and co-localization with aSMA::R26 +ve cells in the striatum 1 week following injury. There was no difference in density of total aSMA::R26 +ve cells (green) or aSMA::R26 +ve cells associated with CD31 +ve blood vessels (red, one-way ANOVA, n = 3-6 mice/group).
(F and G) The injury site was marked by robust astrocytosis (white, GFAP, F) and Dcx +ve neuroblasts (red, F and G) surrounding the infarct area at 1 week postinjury. Confocal analysis and quantification revealed a robust neurogenic response (Dcx +ve cell density) following striatal injury (G), but none of the Dcx +ve cells co-expressed reporter protein (green) at either 1 or 4 weeks post-stroke (* p < 0.01, one-way ANOVA followed by a Tukey's post hoc test, n = 3-6 mice/group). FoxJ1 is also expressed in a subset of neurogenic cells (Beckervordersandforth et al., 2010) . Induction of labeling at P6 or P21 in the FoxJ1CreER T2 system results in mature neurons being labeled in the adult brain (Benner et al., 2013; Jacquet et al., 2011) , whereas recombination during development or adulthood in the aSMACreER T2 system does not. Fate-mapping of labelled cells in the rat brain using a FoxJ1 piggyBac system also shows postnatal neurogenesis (Devaraju et al., 2013) . Since radial glia cells become committed to an ependymal or type B NSC fate at E15.5 (Fuentealba et al., 2015) , the FoxJ1-CreER T2 system must concomitantly target a subpopulation of postnatal V-SVZ neural progenitors or stem cells outside of ependymal cells, whereas the aSMACreER T2 system appears to exclude these NSCs or progenitors. CD133-FACS-sorted ependymal cells have been reported to generate clonally derived neurosphere colonies in vitro (Coskun et al., 2008) , and CD133-immunoreactive ependymal cells have also been reported to proliferate in vivo (Luo et al., 2015) ; however, both these results are confounded because CD133 expression is found in all NSCs within the postnatal V-SVZ (Beckervordersandforth et al., 2010; Codega et al., 2014) . Our data, collected with strict exclusion of the NSC lineage, shows for the first time that ependymal cells do not proliferate in response to known NSC mitogens in vitro or in vivo.
Recently, single-cell transcriptomics has highlighted the inherent heterogeneity of adult V-SVZ neural stem cells at the single-cell level (Dulken et al., 2017; Llorens-Bobadilla et al., 2015) . However, the ependymal cell, which is a major component of the V-SVZ neurogenic niche and has been proposed to be a stem cell itself, has been difficult to study alongside NSCs due to the aforementioned lack of prospective isolation techniques (Beckervordersandforth et al., 2010 (Luo et al., 2015) . These cells were found to express angiogenic receptors like Flt1 and Kdr, which they interpreted as being indicative of a ''dormant'' NSC state, poised for activation under conditions such as brain injury, where levels of angiogenic factors like VEGF are significantly increased in situ (Carlé n et al., 2009; Thau-Zuchman et al., 2010) . However, our transcriptional profiling of the large majority of aSMA::tdTomato +ve Sox2-GFP +ve ependymal cells shows that they do not express Flt1 or Kdr. A key finding is that our transcriptomic analysis captures a rare population of Flt1-expressing cells that shows almost complete concordance with the ''ependymal'' signature identified by Luo et al. (2015) . These Flt1-expressing cells showed marked separation from our ependymal cell cluster and did not exhibit hallmark ependymal features such as expression of cilia-related genes. Thus, while it is possible that Flt1-expressing cells represent a rare subset of ependymal cells, we contend that this rare population identified in both studies does not represent ependymal cells at large. Even if rare Flt1-expressing ependymal cells are present, they are not likely to be dormant neural stem cells, since we observed no neural stem or progenitor characteristics in our recombined cells under any of our stem cell stimulating conditions. A growing body of research suggests that mature, differentiated tissue cell types may be able to de-differentiate into stem or progenitor cells, or trans-differentiate into alternative identities (Merrell and Stanger, 2016) . In the brain, cell types that are otherwise non-neurogenic, such as parenchymal astrocytes, can be reportedly induced into a neurogenic state in vivo following brain injury (Magnusson et al., 2014) , with similar claims being made for ependymal cells using a FoxJ1-driven lineage tracing strategy (Carlé n et al., 2009 ). However, recently, further investigations of FoxJ1-driven lineage tracing in stroke has found minimal, if any, direct stem-cell-like contribution to sites of injury (Muthusamy et al., 2018) . We performed striatal hemorrhagic stroke injury, which provides a broad range of injury etiologies (Lok et al., 2011) , and thus multiple routes of possible ependymal cell ''induction'' to test whether ependymal cells in the adult brain could be induced into neurogenesis by brain injury. Still, we found no evidence for ependymal cell mitosis, ependymal cell loss, or emigration from their niche. Rather, ependymal cells responded to the injury with acute expression of GFAP, as has been reported following ischemic (middle cerebral artery occlusion) injury (Young et al., 2013) .
It could be argued that a subset of ependymal cells in the V-SVZ are in fact neurogenic but escape labeling by the aSMACreER T2 reporter system. If so, this does not represent ependymal cell function at large, considering our system targets the overwhelming majority of ependymal cells. Although our quantification suggests that we label 71% of cells lining the V-SVZ with our reporter system, this is likely an underestimation of the actual number of ependymal cells that are represented by aSMA and share their unique transcriptional profile. Perhaps the most significant factor affecting ependymal cell labeling in our system is that recombination efficiency using the tamoxifen-inducible Cre-lox system is never complete, so some aSMACreER T2 -expressing ependymal cells have escaped recombination. This is supported by our single-cell RNA-seq data, where 23% of cells in our ependymal cell cluster were not captured by aSMA::tdTomato labeling but were instead captured as only Sox2-GFP +ve . Furthermore, only 63% of cells that were in the ependymal cell cluster and labelled by aSMA::tdTomato +ve showed detectable expression of Acta2 at the time of RNA collection, and 41% of cells in the ependymal cluster and labeled by Sox2-GFP +ve alone showed expression of Acta2. This suggests that aSMA expression in ependymal cells in the adult V-SVZ is dynamic, possibly above and beyond the stochastic nature of transcriptional activity (Raj and van Oudenaarden, 2008) . These factors limit the ability to make definitive conclusions about cell populations on a singletranscript level, emphasizing one of the unique insights provided by single-cell RNA-seq: the ability to assess cell populations across multiple transcripts to more accurately define cellular phenotypes. That said, our results together suggest that the vast majority of ependymal cells do not function as latent NSCs or progenitors and are not induced to acquire such properties following brain insult or exogenous growth actor stimulation.
Our work begins to comprehensively identify the salient differences (beyond the intriguing similarities) between ependymal cells and NSCs. Interestingly, hierarchical clustering placed qNSCs closer to ependymal cells than to aNSCs and neuroblasts, yet ependymal cells show a notable lack of stem-celllike abilities. We surmise that post-translational modification or repression may be a critical mechanism underlying their divergent functions and will be investigated in future studies. Interestingly, our analysis did not find any gene expression pattern showing consistent overdispersion in all NSCs and an absence in ependymal cells, suggesting that there is no gene set that qualifies stemness across all NSCs. Instead, we find that there is a transcriptional program unique to qNSCs containing largely uncharacterized gene sets. There is significant heterogeneity within qNSCs in the expression of fate-specifying transcription factors, and only a small number of these transcription factors show correlated expression (Llorens-Bobadilla et al., 2015) . Thus, the genes conferring stemness to qNSCs may be highly heterogenous, small in number, and unique to each individual cell in relation to its ultimate fate or spatial location. Nevertheless, we did find one gene set that exhibited relative homogeneity in qNSCs and was enriched in the glutamine-family amino-acid metabolic process and nervous system development. We suspect that these genes may be necessary to support the quiescent neural stem cell state. Although ependymal cells exhibit shared gene sets with both qNSCs and aNSCs (most likely due to their shared developmental origin), the ependymal cell signature was also exclusively driven by many gene sets related to cilia, appearing to be the differentiating profile that clearly distinguished them from the entire neural stem and progenitor cell lineage.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal work was carried out in accordance with the guidelines and regulations of the CCAC and received prior approval from the University of Calgary's Animal Care Committee (protocol AC14-0019). Adult mice of both sexes (2-6 months of age) on a C57BL/6 background were used for experiments. To induce embryonic CreER T2 recombination, a pregnant mother was given 2 mg of tamoxifen via oral gavage on embryonic day 17. All animals undergoing surgical procedures received pre-and post-operative buprenorphine analgesia (0.05mg/kg). See below for detailed surgical procedures. To label proliferating cells following stroke induction or growth factor infusions, 5-ethnyl-2'-deoxyuridine (EdU; Carbosynth) was injected intraperitoneally (50 mg/kg). Before tissue collection, mice were euthanized with an overdose of sodium pentobarbital and transcardially perfused with 20 mL of PBS and then cold 4% PFA. Dissected brains were post-fixed in 4% PFA at 4 C overnight and subsequently allowed to equilibrate in 30% sucrose at 4 C overnight, before finally embedding in cryoprotectant (VWR Clear Frozen Section Compound) for storage at -80 C. The rostral-caudal axis of the V-SVZ was cut in coronal sections (20 mm) using a cryostat (Leica) and stored at -80 C until further use.
Intracerebral Hemorrhagic Stroke
Animals were anaesthetized with isoflurane, subsequently mounted into a stereotaxic frame and maintained on 1%-2% isoflurane anesthesia throughout the surgery. Mice received either 0.5 mL injections of 1x PBS as control or Collagenase IV (Worthington; 150U/mL) dissolved in 1x PBS to induce an intracerebral hemorrhage. Mice were stratified to achieve close to equal representation of gender and age in each group. For stereotaxic injections, a midline scalp incision was made, followed by a small burr hole and puncturing of the dura. Mice received consecutive unilateral stereotaxic injections of these drugs at two depths into the right striatum at: AP +0.5mm, LM +1.5mm, and DV -3.5mm/-2.7mm using a pulled glass injection needle, with the needle left in following each injection for 10 mins to prevent backflow. Specifically, mice received 280 nL at DV 3.5 mm, and 210 nL at DV -2.7 mm, followed by an additional 5 mins backflow wait time at DV -2.0 mm. Surgeons were not blinded to the agent being injected. Mice also received subcutaneous buprenorphine injections (0.05 mg/kg) at the time of surgery and daily for two days post-surgery. Brains were collected 1 or 4 weeks following stroke induction.
Stereotactic Injection of Growth Factors
Animals were anaesthetized with isoflurane, subsequently mounted into a stereotaxic frame and maintained on 1%-2% isoflurane anesthesia throughout the surgery. Mice received either 1 mL injections of 1x PBS as control or VEGF (1 mg/mL; Peprotech) and bFGF (1 mg/mL; Sigma) dissolved in 1 x PBS as growth factor stimulation. Surgeons were not blinded to the agent being injected. Mice were stratified to achieve close to equal representation of gender and age in each group. Mice received a unilateral stereotaxic injection of these agents into the right lateral ventricle at: AP +0.80 mm, LM +1.25 mm, and DV 2.5 mm using a pulled glass injection needle, with the needle left in place for 15 mins following the injection. Brains were collected 1 week following VEGF/bFGF stimulation.
Immunohistochemistry, EdU staining and Imaging
For immunohistochemical analysis, sections were permeabilized by incubating in 0.5% Triton X-100 in blocking solution (5% bovine serum albumin (BSA) in PBS) for 1 hr at room temperature. Then, sections were treated with primary antibodies (1:200) in 0.1% Triton X-100 in PBS and left at 4 C overnight. Subsequently, sections were washed twice in PBS and incubated with secondary antibodies (1:200, Alexa) in PBS for 2h at room temperature, then washed thrice in PBS, stained for nuclei using Hoestch-33258 and mounted using Permafluor mountant. The following primary antibodies were used: anti-S100a/b, anti-Ki67, anti-Dcx, anti-Sox2, anti-GFAP, anti-CD31, anti-Nestin, anti-GFP, anti-Acetylated Tubulin, APC-conjugated anti-CD133, anti-Integrin a9, anti-VEGFR1/Flt1, antiFibronectin. After immunohistochemical staining, sections were stained for EdU using a Click-iT EdU Alexa Fluor 555 kit according to the manufacturer's instructions. All immunohistochemical stains were confirmed positive with appropriate no primary (secondary alone) controls. Sections were imaged using a Leica SP8 confocal microscope (63x objective, 15-25 serial z-stacks every 0.5 mm-1.0 mm).
FACS Sorting and culturing
The lateral wall of lateral ventricles (at the V-SVZ) from adult mice (n = 5) were microdissected and enzymatically dissociated with Papain (Worthington, 30 U/mL with 330 mg/mL L-Cysteine in HBSS) at 37 C for 30 mins with trituration every 10 min. Cell suspensions were then filtered through a 40 mm Nylon cell strainer to obtain a single cell suspension. Liberated cells were re-suspended in 0.5% BSA in HBSS before FACS purification. For FACS purification/sorting, a stringent initial gate was used to exclude debris, and cell doublets. Wildtype cells were used as negative control to determine gates for detection of eYFP, GFP, tdTomato-fluorescence, then cells from purification and plated at 10 cells/mL directly onto PDL/Laminin coated 96-well plates containing standard neurosphere growth media (1% B27, 1% P/S, 50 ng/mL EGF, 50 ng/mL FGF, with or without 50ng/mL VEGF (Peprotech), in high-glucose DMEM and F12 (3:1)). Cells were left in culture for seven days, with supplementation of growth factors every 3 days. For co-culture experiments with embryonic neural stem cells, the brains of 5 wildtype E13 C57/Bl6 mice were dissociated into a single-cell suspension as described above. For co-culture and conditioned media experiments, primary embryonic NSCs were grown at a density of 30,000 cells/mL with passages using TrypLE for 10 mins every 5-7 days. Floating colonies were dissociated to single cells before re-plating along with sorted cells at a 5:1 ratio (embryonic NSCs to sorted aSMA-YFP +ve ependymal cells). Conditioned media was collected from P1 spheres at optimal passaging density and stored at -80 C. For conditioned media treatment, neurosphere growth media was substituted for conditioned media at a 1:1 ratio at the time of sorting and supplemented with 1% B27, 1% P/S and growth factors (EGF/FGF with or without VEGF) in identical concentrations to experiments described above. Cells were pulsed with growth factors every 3 days. In vitro images were taken with 20x LD Axioplan objectives on a Zeiss Observer epifluorescence microscope.
Single cell library preparation and RNA-sequencing As described above, Fig S3A) and prepared single-cell sequencing libraries for each sample in parallel. All cells were processed according to 10X Genomics Chromium Single Cell 3 0 Reagent Guidelines (v2 Chemistry; https://support.10xgenomics.com/single-cell-gene-expression). Briefly, cells were partitioned into nanoliter-scale Gel Bead-In-EMulsions (GEMs) using 10X GemCode Technology. Primers containing (i) an Illumina R1 sequence, (ii) a 16 bp 10x barcode, (iii) a 10 bp Unique Molecular Identifier (UMI) and (iv) a poly-dT primer sequence were incubated with partitioned cells resulting in barcoded, full-length cDNA from poly-adenylated mRNA. Silane magnetic beads were used to remove leftover biochemical reagents/primers, then cDNA was amplified by PCR. Enzymatic Fragmentation and Size Selection was used to optimize cDNA amplicon size prior to library construction. R1 (read 1 primer sequence) were added during GEM incubation, whereas P5, P7, a sample index (i7), and R2 (read 2 primer sequence) were added during library construction via End Repair, A-tailing, Adaptor Ligation and PCR. Quality control and quantification was performed using a Kapa Library Quantification qPCR kit (Kapa Biosystems). Sequencing was performed using Illumina HiSeq 2500 (read 1 26 cycles, i7 Index 8 cycles, Read 2 98 cycles). Each sample was sequenced to an average depth of 50 million total reads. This resulted in an average read depth of 170 000 reads/cell for Library ID 1 and 2, and $44 000 reads/cell for Library ID 3 (Fig S3A) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Information for animal and experimental replicates can be found in the results section and in the figure legends. Replicate numbers were set at similar numbers to experiments outlined in previous publications that assessed neural stem cell responses in a similar fashion to the current manuscript (Ottone et al., 2014) . All statistical analysis was performed using GraphPad Prism 5 unless otherwise stated. For comparisons of groups across multiple groups, a one-way analysis of variance (ANOVA) followed by Tukey's post-hoc comparison was used. For comparisons of groups across 2 groups, an unpaired Student's t test was used. p values < 0.05 was considered significant. An F test was done concurrently and group variances were not found to be significantly different.
All quantification of immunostaining experiments was performed while blinded to the groups. All quantitative analysis at the V-SVZ was normalized to the total length of the lateral wall analyzed and contained a defined region >500 mm and 60 mm depth into the brain parenchyma from the lateral ventricle. For growth factor injection experiment, all V-SVZ walls were also imaged adjacent to the injection site. The proportion of EdU incorporation in reporter-labelled ependymal cells, GFAP +ve cells or Dcx +ve cells was quantified from z-stacked confocal images and normalized to the total area of tissue analyzed. A two-tailed Student's t test was used to compare GFAP/EdU +ve and total EdU +ve cells in control (n = 3 animals) vs growth factor injection (n = 3 animals) groups. For stroke experiments, all V-SVZ walls were imaged adjacent to the core of the injury site and compared to ependymal cells in the V-SVZ of PBS control injections or to lateral wall of contralateral hemisphere. To quantify the ependymal cell numbers following stroke, the number of recombined cells lining the lateral walls ipsilateral to the injury site was normalized to the contralateral lateral wall, and the mean from three serially sectioned brain slices/animal containing the stroke injury was taken. For quantification of neuroblasts at the rim of the injury site, the number of Dcx +ve cells within a 1mm 2 region in the striatum was counted. A one-way ANOVA followed by Tukey's post-hoc test was used for all analyses to compare control (n = 3 animals) and injury (1 week: n = 3 animals; 4 week: n = 6 animals).
For in vitro experiments, colony number counts were performed at 1 week post-seeding for each group in each independent experiment under a 20x LD Axioplan brightfield objective on a Zeiss Observer microscope. The number of colonies exceeding 50 mm in size were quantified. Colony counts were averaged across all wells collected for each group. All groups were compared to each other using a one-way ANOVA, followed by Tukey's post-hoc test (n = 4 independent trials). Ependymal cell analysis using aSMACreER-T2 ::ROSA26 tdTomato /Sox2 tm2HochGFP cells were replicated as 3 independent trials.
For quantification of single cell RNA-seq data, firstly unsupervised clustering of cells was performed. A selection of highly variable genes (2985 genes) was obtained and used for principle component analysis (Fig S3E, F) . Significant principle components were determined (PCs 1 through 20) using JackStraw analysis and visualization of heatmaps focusing on PCs 12 to 20. PCs 1 to 20 were used for graph based clustering (at res = 0.4) to identify distinct groups of cells. These groups were projected onto tSNE analysis run using previously computed principle components 1 to 20. Expression of selected marker genes was used to classify each of the 9 cell clusters identified by graph-based clustering. Then, marker genes for each cell cluster were identified using the likelihood-ratio test for single cell gene expression, and the top 5 markers for each cluster (based on average difference compared to remaining cells) were selected and plotted on a heatmap. Importantly, individual parallel processing of each sample nor differences in total cell number between each sample did not affect results as evidenced by remarkable concordant clustering of Library ID 2 and 3 ( Figure S3A ).
For PAGODA analysis, cells classified as OL/OPCs, microglia and both undefined cell populations were excluded before beginning pathway and gene set overdispersion analysis. The scde (v1.99.4) R package was used for carrying out this analysis. After building error models for each cell, and normalizing gene expression magnitudes, genes were grouped into gene sets corresponding to preannotated unique GO terms and a total of 150 novel 'de novo' gene sets. Weighted PCA on these gene sets was run using 1 principle component, as we wanted to identify gene sets overdispersed in unique cell populations. Then, hierarchical clustering was performed to order 5 populations. We then explored the pre-annotated and novel gene sets overdispersed in various aspects corresponding to gene expression signatures in each cell population. Specifically, we identified the top 3 gene sets overdispersed in the aspect exclusively specifying qNSCs and identified the top 10 genes (ordered by normalized variance magnitude for each gene) from each of the 3 gene sets.
DATA AND SOFTWARE AVAILABILITY
The RNA-seq data reported in this study has been deposited under GEO: GSE100320. A and B) Immunohistochemical analysis of Integrin a9 (Int a9, A) and CD31 (B) revealed that other recombined cells found throughout the brain were smooth muscle cells associated with CD31
+ve blood vessels and a previously described rare population of Integrin a9 +ve densely fibrous putative pericyte-precursors.
Scale bars: 20 mm (A and B) .
(legend on next page) Figure S2 . RNA-Seq Experiment Metrics and Quality Control, Related to Figure 3 
